

參考資料

1. Hong Kong Cancer Registry, Hospital Authority. Female Breast Cancer in 2023. Published August 2025. Accessed July 17, 2026. https://www3.ha.org.hk/cancereg/pdf/factsheet/2023/breast_2023.pdf
2. International Agency for Research on Cancer. *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 98. Painting, Firefighting, and Shiftwork*. Lyon: International Agency for Research on Cancer; 2010.
3. International Agency for Research on Cancer. List of classifications by cancer sites with sufficient or limited evidence in humans, IARC Monographs Volumes 1 to 141. Updated May 18, 2026. Accessed July 17, 2026. https://monographs.iarc.who.int/wp-content/uploads/2019/07/Classifications_by_cancer_site.pdf
4. Papantoniou K, Castaño-Vinyals G, Espinosa A, et al. Breast cancer risk and night shift work in a case-control study in a Spanish population. *Eur J Epidemiol*. 2016;31(9):867-878. doi:10.1007/s10654-015-0073-y
5. Census and Statistics Department (HK). 2025 Report on Annual Earnings and Hours Survey. Published March 2026. Accessed July 17, 2026. https://www.censtatd.gov.hk/en/wbr.html?ecode=B10500142025AN25&scode=210#section_5
6. Hvidberg L, Pedersen AF, Wulff CN, Vedsted P. Cancer awareness and socio-economic position: Results from a population-based study in Denmark. *BMC Cancer*. 2014;14(1):581. doi:10.1186/1471-2407-14-581
7. Gürdal SÖ, Saraçoğlu GV, Oran EŞ, Yankol Y, Soybir GR. The effects of educational level on breast cancer awareness: A cross-sectional study in Turkey. *Asian Pac J Cancer Prev*. 2012;13(1):295-300. doi:10.7314/APJCP.2012.13.1.295
8. Yeung MPS, Chan EYY, Wong SYS, Yip BHK, Cheung PSY. Hong Kong female's breast cancer awareness measure: Cross-sectional survey. *World J Clin Oncol*. 2019;10(2):98-109. doi:10.5306/wjco.v10.i2.98
9. Hong Kong Breast Cancer Foundation. *Hong Kong Breast Cancer Registry Bulletin Issue 2: Socio-Economic Disparities in Breast Cancer Screening Practice and Cancer Staging in Hong Kong*. Hong Kong Breast Cancer Foundation; 2012.
10. Jansen LA, Backstein RM, Brown MH. Breast size and breast cancer: A systematic review. *J Plast Reconstr Aesthet Surg*. 2014;67(12):1615-1623. doi:10.1016/j.bjps.2014.10.001
11. Li X, Zhou C, Wu Y, Chen X. Relationship between formulaic breast volume and risk of breast cancer based on linear measurements. *BMC Cancer*. 2020;20:989. doi:10.1186/s12885-020-07499-5
12. del Carmen MG, Halpern EF, Kopans DB, et al. Mammographic breast density and race. *AJR Am J Roentgenol*. 2007;188(4):1147-1150. doi:10.2214/AJR.06.0619
13. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). *Cancer Causes Control*. 1995;6(5):431-438. doi:10.1007/BF00052183
14. Ko SY, Kim MJ. Associations of age, body mass index, and breast size with mammographic breast density in Korean women. *J Med Life Sci*. 2023;20(1):21-31. doi:10.22730/jmls.2023.20.1.21



15. Lynge E, Vejborg I, Lillholm M, Nielsen M, Napolitano G, von Euler-Chelpin M. Breast density and risk of breast cancer. *Int J Cancer*. 2023;152(6):1150-1158. doi:10.1002/ijc.34316
16. Non-communicable Disease Branch, Centre for Health Protection, Department of Health (HK). Report of Health Behaviour Survey 2023. Published January 2025. Accessed July 17, 2026. https://www.chp.gov.hk/files/pdf/dh_hbs_2023_report_eng.pdf
17. Cancer: Breast cancer. In: U.S. Department of Health and Human Services. *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014:230.
18. Yeo W, Yuen LW, Tsoi KKF, et al. Modifiable risk factors including self-perceived stress for breast cancer in Hong Kong: A case-control study of 10 757 subject. *Clin Med Insights Oncol*. 2025;19:11795549251314434. doi:10.1177/11795549251314434
19. World Cancer Research Fund / American Institute for Cancer Research. Diet, nutrition, physical activity and breast cancer. *Continuous Update Project Expert Report 2018*. Published May 2018. Accessed July 20, 2026. <https://www.wcrf.org/wp-content/uploads/2024/10/Breast-cancer-report.pdf>
20. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis. *PLoS One*. 2012;7(12):e51446. doi:10.1371/journal.pone.0051446
21. Non-communicable Disease Branch, Centre for Health Protection, Department of Health (HK). Report of Population Health Survey 2020-22 (Part II). Published April 2023. Accessed July 20, 2026. https://www.chp.gov.hk/files/pdf/dh_phs_2020-22_part_2_report_eng_rectified.pdf
22. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. *Lancet*. 2001;358(9291):1389-1399. doi:10.1016/S0140-6736(01)06524-2
23. Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: A systematic review and meta-analysis. *Int J Cancer*. 1997;71(5):800-809. doi:10.1002/(sici)1097-0215(19970529)71:5<800::aid-ijc18>3.0.co;2-b
24. Kwong A, Shin VY, Ho JCW, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *J Med Genet*. 2016;53:15-23. doi:10.1136/jmedgenet-2015-103132
25. Kwong A, Shin VY, Au CH, et al. Detection of germline mutation in hereditary breast and/or ovarian cancers by next-generation sequencing on a four-gene panel. *J Mol Diagn*. 2016;18(4):580-594. doi:10.1016/j.jmoldx.2016.03.005
26. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Elmasri OA, Al-Foheidi M. Risk of second breast cancer in female Hodgkin's lymphoma survivors: A meta-analysis. *BMC Cancer*. 2012;12:197. doi:10.1186/1471-2407-12-197
27. Caini S, Boniol M, Botteri E, et al. The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis. *J Dermatol Sci*. 2014;75(1):3-9. doi:10.1016/j.jdermsci.2014.02.007

28. Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. *BMC Cancer*. 2014;14:94. doi:10.1186/1471-2407-14-94
29. Youlten DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: A retrospective cohort study. *BMC Cancer*. 2011;11:83. doi:10.1186/1471-2407-11-83
30. Chuang SC, Scélo G, Lee YCA, et al. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer*. 2010;102(7):1190-1195. doi:10.1038/sj.bjc.6605616
31. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. *J Clin Oncol*. 2009;27(6):967-973. doi:10.1200/JCO.2008.18.4549
32. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: A meta-analysis. *J Cancer Res Clin Oncol*. 2011;137:1053-1060. doi:10.1007/s00432-011-0979-z
33. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*. 1996;347(9017):1713-1727. doi:10.1016/S0140-6736(96)90806-5
34. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med*. 2017;377(23):2228-2239. doi:10.1056/NEJMoa1700732
35. Urban M, Banks E, Egger S, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: Case-control study. *PLoS Med*. 2012;9(3):e1001182. doi:10.1371/journal.pmed.1001182
36. Li CI, Beaber EF, Tang MTC, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. *Cancer Res*. 2012;72(8):2028-2035. doi:10.1158/0008-5472.CAN-11-4064
37. Sweeney C, Giuliano AR, Baumgartner KB, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. *Int J Cancer*. 2007;121(11):2517-2523. doi:10.1002/ijc.22970
38. Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. *Am J Epidemiol*. 2000;151(4):396-403. doi:10.1093/oxfordjournals.aje.a010219
39. Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. *Contraception*. 2004;69(5):353-360. doi:10.1016/j.contraception.2003.12.015
40. Department of Health (HK). LC Paper No. CB(2)1269/19-20(03) Legislative Council Panel on Health Services. Breast Cancer Screening. Issued July 6, 2020. Accessed July 20, 2026. <https://www.legco.gov.hk/yr19-20/english/panels/hs/papers/hs20200710cb2-1269-3-e.pdf>
41. Breast Cancer Screening Pilot Programme to be launched on September 6 (with photos). HKSAR Government Press Releases. Published September 2, 2021. Accessed July 20, 2026. <https://www.info.gov.hk/gia/general/202109/02/P2021090100619.htm>



42. DH to subsidise high-risk women for breast cancer screening services from June 10 (with photo/video). HKSAR Government Press Releases. Published May 29, 2025. Accessed July 20, 2026. <https://www.info.gov.hk/gia/general/202505/29/P2025052900401.htm>
43. Roth MY, Elmore JG, Yi-Frazier JP, Reisch LM, Oster NV, Miglioretti DL. Self-detection remains a key method of breast cancer detection for U.S. women. *J Womens Health (Larchmt)*. 2011;20(8):1135-1139. doi:10.1089/jwh.2010.2493
44. Ernst MF, Roukema JA, Coebergh JW, et al. Breast cancers found by screening: Earlier detection, lower malignant potential or both? *Breast Cancer Res Treat*. 2002;76(1):19-25. doi:10.1023/A:1020213817562
45. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: A systematic review. *Lancet*. 1999;353(9159):1119-1126. doi:10.1016/S0140-6736(99)02143-1
46. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer (Version 5.2020). Published July 2020.
47. Amin MB, Edge S, Greene F, et al. (eds). *AJCC Cancer Staging Manual (8th Edition)*. New York, NY: Springer International Publishing; 2017.
48. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med*. 2018;142(11):1364-1382. doi:10.5858/arpa.2018-0902-SA
49. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. *Ann Oncol*. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304
50. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer (Version 6.2026). Published July 2026.
51. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: An overview. *BMC Med*. 2015;13:195. doi:10.1186/s12916-015-0439-8
52. Byers T, Nestle M, McTiernan A, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. *CA Cancer J Clin*. 2002;52(2):92-119. doi:10.3322/canjclin.52.2.92